Cancer treatment has changed significantly over the past few decades. Along with surgery, chemotherapy, radiation therapy, and targeted therapy, immunotherapy has become an important treatment option for many types of cancer. Unlike treatments that primarily attack cancer cells directly, immunotherapy works by helping the body's immune system recognize and fight cancer more effectively.
For patients and families exploring immunotherapy in Jaipur, understanding the medicines used in this treatment can make discussions with an oncologist easier. Immunotherapy is not a single medicine or treatment method. It includes several categories of medicines, each designed to activate, strengthen, or redirect the immune response against cancer.
What Is Immunotherapy in Cancer Treatment?
The immune system naturally protects the body from infections and abnormal cells. However, cancer cells can develop ways to hide from immune cells or suppress the body's immune response. Immunotherapy aims to overcome some of these mechanisms and help immune cells recognize and attack cancer cells.
Depending on the cancer type, stage, biomarkers, previous treatments, and overall health, immunotherapy may be used alone or alongside chemotherapy, radiation therapy, surgery, or other cancer medicines.
Importantly, immunotherapy is not appropriate for every patient. Doctors may use biomarker and other diagnostic testing to determine whether a particular immunotherapy is likely to benefit an individual patient.
1. Immune Checkpoint Inhibitors
Immune checkpoint inhibitors are among the most widely recognized immunotherapy medicines used in modern cancer care.
The immune system has natural "checkpoints" that prevent immune cells from attacking healthy tissues excessively. Cancer cells can sometimes take advantage of these checkpoints to avoid being destroyed. Checkpoint inhibitor medicines block specific checkpoint signals, allowing T cells to respond more strongly against cancer cells.
Common checkpoint targets include:
- PD-1
- PD-L1
- CTLA-4
- LAG-3
Examples of checkpoint inhibitor medicines include pembrolizumab, nivolumab, cemiplimab, atezolizumab, durvalumab, ipilimumab, tremelimumab, and relatlimab. The specific medicine depends on the cancer and the patient's clinical and biomarker profile.
These medicines are used in several cancers, including selected cases of lung cancer, melanoma, kidney cancer, bladder cancer, head and neck cancers, and other malignancies.
2. Monoclonal Antibodies
Monoclonal antibodies are laboratory-created proteins designed to recognize specific targets. Some monoclonal antibodies are considered immunotherapy because they help the immune system identify or attack cancer cells. Others function primarily as targeted therapies, so the terms should not always be treated as interchangeable.
For example, some antibodies can attach to proteins on cancer cells and mark them for destruction by immune cells. Other antibody medicines can interfere with signals that cancer cells use to grow.
Examples include medicines such as rituximab and certain checkpoint inhibitors. Some monoclonal antibodies can also be combined with chemotherapy drugs or radioactive substances to deliver treatment more specifically toward cancer cells.
3. Cytokines
Cytokines are proteins that help regulate communication between immune cells. Certain cytokines can be manufactured as medicines and used to stimulate immune activity against cancer.
Two important groups used in cancer treatment include interleukins and interferons. Depending on the disease and treatment plan, these medicines may be used alone or alongside other cancer therapies.
Cytokine-based treatments are used less broadly than some modern checkpoint inhibitors, but they remain an important part of the history and development of cancer immunotherapy.
4. Cancer Treatment Vaccines
Cancer treatment vaccines are different from vaccines designed to prevent infections. They are intended for people who already have cancer and work by helping the immune system recognize specific cancer-related antigens.
The goal is to train or strengthen the immune response so immune cells can identify and attack cancer cells carrying particular targets.
Cancer treatment vaccines are used for selected cancers and specific clinical situations rather than being a universal treatment for all cancer patients.
5. T-Cell Transfer Therapy
T-cell transfer therapy is another form of immunotherapy in which immune cells are collected and modified, selected, or multiplied outside the body before being returned to the patient.
One well-known approach is CAR T-cell therapy, in which a patient's T cells are genetically modified so they can better recognize specific cancer targets. Another approach involves tumor-infiltrating lymphocytes (TILs), which are immune cells found within a tumor and can be expanded in a laboratory before being returned to the patient.
These therapies can be highly specialized and are mainly used for selected cancers and clinical circumstances.
6. Oncolytic Virus Therapy
Oncolytic virus therapy uses specially modified viruses that can infect and damage certain cancer cells while also stimulating an immune response against the tumor.
The approach is based on two potential effects: directly affecting tumor cells and encouraging the immune system to recognize the cancer. It represents an evolving area of cancer treatment and is available only for selected indications.
How Are Immunotherapy Medicines Selected?
Choosing an immunotherapy medicine is not simply a matter of selecting the "strongest" drug. Cancer treatment needs to be personalized.
Doctors may consider:
- Type and stage of cancer
- Tumor location and spread
- Previous treatments
- Overall health and other medical factors
- Biomarker results
- PD-L1 expression in appropriate cancers
- Certain genetic or molecular characteristics
- Potential benefits and risks of treatment
Biomarker testing can help doctors identify patients who may be more likely to benefit from particular immunotherapies. However, a biomarker result does not guarantee that treatment will work.
For patients considering immunotherapy in Jaipur, discussing biomarker testing and the purpose of the recommended medicine with a qualified oncologist can be an important step before starting treatment.
Can Immunotherapy Improve Cancer Survival?
Immunotherapy has produced long-lasting responses in some patients with certain cancers, particularly where the cancer has characteristics that make it responsive to immune-based treatment. However, its effectiveness varies considerably between individuals and cancer types.
Immunotherapy should therefore not be described as a guaranteed cure or as a treatment that will extend survival for every patient. In some situations, it may control cancer for a significant period, reduce the risk of recurrence, or improve outcomes when combined with other treatments.
Cancer care teams may also combine immunotherapy with chemotherapy, radiation therapy, surgery, targeted therapy, or another immunotherapy when clinical evidence supports the approach.
What About Immunotherapy Side Effects?
Because immunotherapy activates or changes immune activity, its side effects can differ from those commonly associated with traditional chemotherapy.
Patients may experience fatigue, skin reactions, fever, gastrointestinal symptoms, or inflammation. In some cases, the immune system may attack healthy organs, potentially causing inflammation involving the lungs, liver, intestines, thyroid, skin, or other organs.
The severity varies from person to person. Patients receiving immunotherapy should inform their cancer care team about new or unusual symptoms rather than assuming they are normal treatment effects.
Why Specialist Guidance Matters
Immunotherapy medicines require careful selection and monitoring. The same medicine may be appropriate for one cancer type but unsuitable for another. Treatment schedules, combinations, duration, and monitoring requirements can also differ.
Patients should ask their oncologist why a particular immunotherapy has been recommended, whether biomarker testing is needed, what benefits are realistically expected, what side effects require immediate attention, and how treatment will be monitored.
Conclusion
Immunotherapy has become an important part of modern cancer treatment, with medicines ranging from immune checkpoint inhibitors and monoclonal antibodies to cytokines, treatment vaccines, cellular therapies, and oncolytic virus approaches. The right treatment depends on the individual patient's cancer characteristics, biomarkers, overall health, and previous treatment history. Anyone exploring immunotherapy in Jaipur should seek an individualized evaluation from a qualified oncology team rather than relying on general treatment claims. Chirayu Cancer Hospital focuses on providing cancer care based on individual patient needs, helping patients understand available treatment options and make informed decisions in consultation with their medical team.
